The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

Share Price Information for Belluscura (BELL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 7.50
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 1.00 (13.333%)
Open: 8.00
High: 8.00
Low: 8.00
Prev. Close: 8.00
BELL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Belluscura receives certification to ISO standard

10 Nov 2022 07:00

RNS Number : 9055F
Belluscura PLC
10 November 2022
 

10 November 2022

 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

Belluscura plc

("Belluscura" or the "Company")

 

Belluscura receives certification to major ISO standard

 

Belluscura, a leading medical device developer focused on lightweight and portable oxygen enrichment technology, is pleased to announce today that it has been certified as compliant with ISO standards for Quality Management (ISO 13485:2016), allowing for design, development, manufacture and distribution of its portable oxygen concentrators (POC) following an extensive audit process undertaken by leading global assurance provider SGS.

 

The Group's manufacturing facilities in both Texas and China achieved ISO 13485 certification ahead of schedule, following a complete review of our quality systems and processes, including the newly insourced manufacturing facility.

 

The International Organization for Standardization ("ISO") is one of the world's leading standards-settings bodies. The Organization develops standards to ensure the quality, safety and efficiency of products, services and systems; those standards are recognised globally as the benchmark for operational excellence among leading manufacturing companies.

 

The individual standards to which Belluscura is now certified are core to the Company's business. ISO 13485:2016 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. The certification, therefore, enables the Group to apply to distribute the X-PLOR and DISCOV-R in Europe (CE mark), UK (CA mark), China and the rest of the world.

 

 

 

Robert Rauker, CEO of Belluscura plc, said:

 

"This is a hugely significant step for the Group, as ISO 13485 certification will enable the company to begin the process to start distributing its products globally. Our existing market in the US represents approximately 45% of the Portable Oxygen Concentrator market, so this certification more than doubles the available market opportunity for the Group." 

 

"The certification shows the dedication of our team to not only developing a quality product, but to being a leading manufacturer of portable oxygen concentrators. Compliance with this standard will enable Belluscura's commercial development by proving to new customers that the Company adheres to the highest standards of quality management excellence.

 

"It will, therefore, contribute to our growth as we expand production of our X-PLOR® device and the Nomad Biometric™ App, as well as the DISCOV-R™, which we expect to launch in Q1 2023 as the world's first ambulatory dual flow portable oxygen concentrator."

 

ENDS

 

 

For further information, please contact:

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP

Anthony Dyer, Chief Financial Officer

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

MHP Communications (Financial PR and Investor Relations)

Tel: +44 (0)20 3128 8100

Katie Hunt / Pete Lambie / Matthew Taylor

Email: belluscura@mhpc.com

 

 

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.

 

Glossary

X-PLOR® is a lightweight portable oxygen concentrator with user replaceable oxygen enrichment cartridges and direct-charge batteries. Weighing only 3.75 lbs, its AirgonomicTM Design ensures user-friendly experience and maximum comfort. It has multiple Pulse Flow Settings including X-PLORATIONTM Mode (750mL for 10 mins).

 

DISCOV-R™ will deliver 2000mL of continuous flow oxygen and have 8 Pulse Flow Settings. Weighing only 6.5 lbs, it will be the first ambulatory 2L portable oxygen concentrator, producing more oxygen per pound than others in its class.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFSMFUUEESELF
Date   Source Headline
17th Apr 20247:00 amRNSBelluscura Concert Party
11th Apr 202410:23 amRNSHolding(s) in Company
8th Apr 20241:15 pmRNSHolding(s) in Company
5th Apr 20243:48 pmRNSIssue of Equity
2nd Apr 20247:00 amRNSTrading Update
28th Mar 20247:00 amRNSTotal Voting Rights
8th Mar 20244:36 pmRNSOffer Closed
7th Mar 20248:30 amRNSCancellation of Listing and trading
4th Mar 20247:00 amRNSAcceptances level
26th Feb 20247:00 amRNSAcceptances level
22nd Feb 20243:00 pmRNSAcceptances level, issue of equity & AIM Admission
19th Feb 20247:00 amRNSAcceptances level & offer closing
15th Feb 20243:51 pmRNSAcceptances level, issue of equity & AIM Admission
13th Feb 20247:00 amRNSDistribution Agreement & New VP North America
13th Feb 20247:00 amRNSAcceptances Level
12th Feb 20241:44 pmGNWForm 8.3 - Belluscura PLC
9th Feb 20248:16 amRNSOffer becomes wholly unconditional
8th Feb 20243:31 pmRNSAcceptances level, issue of equity & AIM Admission
7th Feb 20244:20 pmRNSOffer Unconditional (subject to AIM Admission)
7th Feb 202411:13 amRNSForm 8.3 - Belluscura Plc
5th Feb 20241:30 pmRNSResult of General Meeting
5th Feb 20247:00 amRNSAcceptances received in respect of the Offer
2nd Feb 202411:24 amRNSForm 8 (OPD) Belluscura plc
2nd Feb 202411:18 amRNSForm 8 (OPD) TMT Acquisition plc
1st Feb 20246:16 pmRNSForm 8 (OPD) TMT Acquisition plc - Amended
1st Feb 20246:14 pmRNSForm 8 (OPD) Belluscura plc - Amended
1st Feb 20242:34 pmGNWForm 8.3 - Belluscura PLC
29th Jan 202411:42 amRNSForm 8.3 - Belluscura PLC
24th Jan 20246:24 pmRNSForm 8.3 - Belluscura PLC
24th Jan 20246:17 pmRNSForm 8.3 - Belluscura
24th Jan 20246:02 pmRNSForm 8.3 - Belluscura PLC - Replacement
24th Jan 20245:49 pmRNSForm 8.3 - Belluscura PLC
24th Jan 20243:25 pmRNSForm 8.3 - Belluscura plc
24th Jan 20243:14 pmRNSHolding(s) in Company
24th Jan 202410:45 amRNSForm 8.3 - Belluscura Plc
23rd Jan 20246:06 pmRNSForm 8.3 - Belluscura plc
23rd Jan 20245:39 pmRNSForm 8.3 - BELLUSCURA PLC
19th Jan 20241:30 pmRNSPosting of Offer Document and Circular
8th Jan 20241:01 pmGNWForm 8.3 - Belluscura PLC
22nd Dec 202312:10 pmRNSExtension to deadline for posting Offer Document
20th Dec 20237:00 amRNSChinese registration and Trading Update
19th Dec 20231:04 pmGNWForm 8.3 - Belluscura PLC
13th Dec 20232:43 pmGNWForm 8.3 - Belluscura PLC
12th Dec 20237:00 amRNSBelluscura Receives Approval in Singapore
28th Nov 20235:00 pmRNSExtension to deadline for posting Offer Document
24th Nov 20232:06 pmGNWForm 8.3 - Belluscura PLC
16th Nov 202312:20 pmRNSForm 8.3 - Belluscura PLC
16th Nov 202312:12 pmRNSForm 8.3 - Belluscura PLC
9th Nov 202311:04 amRNSForm 8.3 - TMT Acquisition PLC
8th Nov 20235:52 pmRNSForm 8.3 - TMT Acquisition plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.